Literature DB >> 15997391

Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.

P S Rangi1, W J Partridge, E S Newlands, A D Waldman.   

Abstract

A 49-year-old woman who had previously received treatment with cytotoxic drugs for metastatic gestational trophoblastic disease (GTD) presented with a witnessed tonic-clonic seizure, headache, confusion and blindness, 6 days after the uneventful administration of a general anaesthetic and 2 months after cessation of chemotherapy. Magnetic resonance imaging showed relatively symmetrical, subcortical, white matter abnormalities, predominantly affecting the occipital, posterior temporal and parietal lobes and the cerebellum. T2-dependent abnormalities and elevated regional apparent diffusion coefficient were present in a pattern typical for posterior reversible encephalopathy syndrome (PRES). The clinical and radiological manifestations were resolved completely with supportive therapy. This case of PRES may be a late complication of gemcitabine or cisplatin therapy precipitated by a general anaesthetic, or associated electrolyte or blood pressure disturbance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997391     DOI: 10.1007/s00234-005-1376-6

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  24 in total

1.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

2.  Elevated plasma endothelin concentrations in cyclosporine-treated patients after bone marrow transplantation.

Authors:  C Haug; T Duell; A Lenich; H J Kolb; A Grünert
Journal:  Bone Marrow Transplant       Date:  1995-07       Impact factor: 5.483

3.  Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases.

Authors:  R B Schwartz; K M Jones; P Kalina; R L Bajakian; M T Mantello; B Garada; B L Holman
Journal:  AJR Am J Roentgenol       Date:  1992-08       Impact factor: 3.959

4.  Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia.

Authors:  P W Schaefer; F S Buonanno; R G Gonzalez; L H Schwamm
Journal:  Stroke       Date:  1997-05       Impact factor: 7.914

5.  Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions.

Authors:  R A Hauser; D M Lacey; M R Knight
Journal:  Arch Neurol       Date:  1988-10

6.  Cyclosporine A stimulates endothelin release.

Authors:  C Haug; T Duell; R Voisard; A Lenich; H J Kolb; V Mickley; V Hombach; A Grünert
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

7.  In vitro effects of fentanyl, methohexital, and thiopental on brain endothelial permeability.

Authors:  S Fischer; D Renz; W Schaper; G F Karliczek
Journal:  Anesthesiology       Date:  1995-02       Impact factor: 7.892

8.  Association between cyclosporin neurotoxicity and hypomagnesaemia.

Authors:  C B Thompson; C H June; K M Sullivan; E D Thomas
Journal:  Lancet       Date:  1984-11-17       Impact factor: 79.321

9.  Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study.

Authors:  L Edvinsson; C Owman; N O Sjöberg
Journal:  Brain Res       Date:  1976-10-22       Impact factor: 3.252

10.  Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.

Authors:  Diego J Covarrubias; Patrick H Luetmer; Norbert G Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

View more
  17 in total

1.  [Acute bilateral loss of vision in posterior reversible encephalopathy syndrome].

Authors:  K S Bonsel; I Oberacher-Velten; K Hufendiek; H Jägle
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

2.  Focal neuronal loss, reversible subcortical focal T2 hypointensity in seizures with a nonketotic hyperglycemic hyperosmolar state.

Authors:  S Raghavendra; R Ashalatha; Sanjeev V Thomas; C Kesavadas
Journal:  Neuroradiology       Date:  2007-01-03       Impact factor: 2.804

3.  Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine.

Authors:  Germán Morís; Renee Ribacoba; Carmen González
Journal:  J Neurol       Date:  2007-03-04       Impact factor: 4.849

Review 4.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

5.  Clinicoradiological factors influencing the reversibility of posterior reversible encephalopathy syndrome: a multicenter study.

Authors:  Ajaya R Pande; Kumiko Ando; Reiichi Ishikura; Yuki Nagami; Yoshihiro Takada; Akihiko Wada; Yoshiyuki Watanabe; Yukio Miki; Akira Uchino; Norio Nakao
Journal:  Radiat Med       Date:  2006-12-25

6.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review.

Authors:  Changqing Xie; Vovanti T Jones
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

7.  Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.

Authors:  Yongen Chang; Gilbert Mbeo; Susan J Littman
Journal:  J Gastrointest Cancer       Date:  2012-09

8.  Factors associated with the presence of postoperative headache in elective surgery patients: a prospective single center cohort study.

Authors:  Paraskevi K Matsota; Theodora C Christodoulopoulou; Chrysanthi Z Batistaki; Chryssa C Arvaniti; Konstantinos I Voumvourakis; Georgia G Kostopanagiotou
Journal:  J Anesth       Date:  2016-11-18       Impact factor: 2.078

9.  Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?

Authors:  Christina Mueller-Mang; Thomas Mang; Agnes Pirker; Katharina Klein; Christine Prchla; Daniela Prayer
Journal:  Neuroradiology       Date:  2009-02-21       Impact factor: 2.804

10.  A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome.

Authors:  Eun Jin Kwon; Se Won Kim; Kwang Ki Kim; Hyung Suk Seo; Do Yeun Kim
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.